Improving Neurodevelopmental ouTcomes After Prenatal Cannabinoid in uTero Exposure

Recruiting N/A Interventional Study
Developmental Delay
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
Up to 7 Days
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
20 (estimated)
Sponsor
IDeA States Pediatric Clinical Trials Network · Research network
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The INTACT trial is a multisite pilot feasibility study aimed at testing the effectiveness of the INTACT Intervention program in improving neurodevelopmental outcomes in infants prenatally exposed to cannabinoids. The trial will enroll 20 birthing parent/infant dyads across three sites and will evaluate feasibility endpoints rather than clinical outcomes. The study duration is 22 months, including…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Birthing Parent * Age of majority, as defined by the state of residency * Cannabinoid use during pregnancy confirmed with self-report * Have the ability to speak, read, and understand English * Birthing parent who delivered at one of the hospitals where study team members have …
Contacts

Song Ounpraseuth, PhD

(501) 686-5647

STOunpraseuth@uams.edu

CONTACT

Matthew Henry, MSc

(501) 686-5647

mhenry3@uams.edu

CONTACT